

AWARD NUMBER: W81XWH-19-1-0513

TITLE: Suppression of GWVI Toxin-Activated Microglia and Pathologies by DREADD

PRINCIPAL INVESTIGATOR: Giulio Maria Pasinetti MD., PhD

CONTRACTING ORGANIZATION: Icahn School of Medicine at Mount Sinai (ISMMS)
1 Gustave L Levy Place
New York, NY 10029-6504

REPORT DATE: September 2020

TYPE OF REPORT: ANNUAL

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE SEPTEMBER 2020		2. REPORT TYPE Annual		3. DATES COVERED 08/15/2019-08/14/2020	
4. TITLE AND SUBTITLE Suppression of GWVI Toxin-Activated Microglia and Pathologies by DREADD				5a. CONTRACT NUMBER W81XWH-19-1-0513	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Giulio Pasinetti MD., PhD E-Mail:giulio.pasinetti@mssm.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Icahn School of Medicine at Mount Sinai (ISMMS) 1 Gustave L Levy Place New York, NY 10029-6504				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Approximately one third of Veterans who served in the Gulf War later developed a chronic multi-symptom illness known as Gulf War Illness (GWI). While the exact cause is unknown, it is believed that persistent exposure to environmental toxins such as pesticides and chemical warfare agents may have interacted with combat-related stress to produce lasting neurological and psychiatric complications among this Veteran population. Neuroinflammation has been increasingly linked with psychiatric and neurological disorders and may play a role in GWI pathology. Microglia are a key mediator of neuroinflammation and the underlying goal of this project is to test the hypothesis that microglial activation acts as a causal factor to produce cognitive and psychiatric disturbances in a mouse model of GWI. In particular, this project will utilized novel Designer Receptors Exclusively Activated by Designer Drugs (DREADD) technology to inactivate microglia in our mouse model of GWI.					
15. SUBJECT TERMS: NONE LISTED					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	8	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page No.</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	6
5. Changes/Problems	6
6. Products	6
7. Participants & Other Collaborating Organizations	7
8. Special Reporting Requirements	8
9. Appendices	8

1. INTRODUCTION

Gulf War Illness represents The overall goal of this DOD funded research study is to develop a novel mouse model of Gulf War Illness (GWI) and test the hypothesis that microglia are a key mediator of GWI neuropathology. In pursuit of these goals, we are validating a Cx3Cr1-dependent designer receptor exclusively activated by a designer drug (DREADD) for the suppression of microglia in mice. In particular, we will use this mouse to test the hypothesis that microglial activation mediates neuroinflammation and behavioral abnormalities after exposure to permethrin and stress.

2. KEYWORDS

Gulf War Illness, microglia, permethrin, stress, pyrethroid, DREADD, learning and memory, depression, anxiety

3. ACCOMPLISHMENTS

a. Major Goals of the Project:

Finalize Breeding of DREADD Mice (Year 1)

- Generate a Breeding colony to produce sufficient numbers of DREADD mice necessary for all experiments.

Validate DREADD mediated microglial activation with LPS (Year 1)

- Use LPS administration to induce microglial activation
- Use inactivate microglia via administration of clozapine-n-oxide to validate technique.

Brain/Plasma Cytokine and FACS of Neuroimmune Cells (Year 1.5-2)

- Collect brains and plasma from mice exposed to permethrin and stress to analyze immune cell populations via FACS

Immunohistochemistry of microglia (Year 2)

- Quantify microglial activation in mouse model of GWI and suppression.

Peripheral Leukocyte Immunophenotyping (Year 2)

- Determine if microglial suppression in DREADD mice affects peripheral immune cell phenotypes.

Animal Behavior Assessments (cognitive) (Year 1)

- Determine if microglial suppression in DREADD mice prevents spatial memory impairments in GWI mouse model.

Animal Behavior Assessments (psychiatric) (Year 2)

- Determine if microglial suppression in DREADD mice prevents spatial memory impairments in GWI mouse model.

b. Accomplishments Under These goals

We proposed to expose mice to Gulf War toxins such as permethrin, and to test the hypothesis that behavioral impairments caused by permethrin were mediated by microglial activation. In pursuit of these goals we have successfully generated a

colony of Cx3Cr1-dependent DREADD mice for suppression of microglia. Additionally, we validated a novel mouse model of GWI by treating mice with 200mg/kg permethrin every day for 14 days followed by 7 days of unpredictable mild stress. Behavioral analysis of the treated mice showed a significant increase in depression like behavior as measured via forced swim test (fig.1). We also analyzed anxiety like behavior using the open field test, and found no significant difference between treatment groups (fig.1). We also collected fixed brains from our GWI mice and performed immunohistochemistry to detect changes in Iba1 and CD68 to measure changes in microglial activation. We are currently in the process of performing sholl analysis to quantify microglial activation on the images generated from these brains. Additionally, we are currently in the process of performing fluorescence activated cell sorting (FACS) using blood and brain tissue from GWI mice. Specifically, we are measuring changes in CD45, CD11b, TLR4, CD14, RAGE, CD86, MHC-II, or CD3, Ly6C, CD19.




Figure 1. Behavioral changes in mouse model of GWI. Mice were exposed to permethrin (200mg/kg, i.p) for 14 days followed by 7 days of unpredictable stress. A) Mice displayed a significant increase in depressive behavior (time spent freezing) during forced swim test. B) No significant differences were detected in anxiety-like behavior as measured by time spent in the center during open field test.

c. Opportunities for Professional Development

Dr. Sean Naughton is a postdoctoral fellow working on the aforementioned research. Dr. Naughton has undergone professional development activities as a result of this work, by presenting the research at the Gulf War Illness State of the Science Virtual Conference 2020.

d. Dissemination of Information to Communities of Interest

Preliminary results were presented at the Gulf War Illness State of the Science Virtual Conference 2020.

The following poster was presented:

Naughton SX, Westfall S, Pasinetti GM “Immune Priming as A Driver of Gulf War Illness Pathology”

Abstract/Poster No. VA-28, Gulf War Illness State of the Science, Virtual Conference August 18-19, 2020

e. Plan for next reporting period

As we move into the next reporting period we plan to examine changes in the proportion of peripheral plasma T helper cells, then determine if suppression of microglia prevents such changes. Specifically, we will collect blood from GWI mice and isolate plasma to characterize immunophenotypes of blood lymphocyte cells using multiparametric FACS. This will allow for characterization of T effector cells and T helper populations in the plasma, respectively. Additionally, we will continue to perform behavioral and immunohistochemical analysis of additional cohorts of animals.

4. Impact

a. What was the impact on the development of the principal discipline(s) of the project?

Nothing to Report

b. What was the impact on other disciplines?

Nothing to Report

c. What was the impact on technology transfer?

Nothing to Report

d. What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS

a. Changes in approach and reasons for change

We initially planned to conduct mouse behavioral studies to assess spatial learning and memory during the first year and anxiety and depressive behaviors during the second year. We instead conducted anxiety and depressive behaviors during the first year and plan to measure spatial memory during the second year. This was because the behavioral tasks for depression and anxiety (forced swim and open field) were easier to perform while adhering to social distancing requirements during the COVID-19 pandemic.

b. Actual or anticipated problems or delays and actions or plans to resolve them

Nothing to Report

c. Changes that had a significant impact on expenditures

Nothing to Report

Significant changes in use or care of human subjects

Nothing to Report

d. Significant changes in use or care of vertebrate animals.

Nothing to Report

e. Significant changes in use of biohazards and/or select agents

Nothing to Report

6. PRODUCTS

a. Journal Publications

Nothing to Report

b. Books or other non-periodical, one-time publications

Nothing to Report

c. Other publications, conference papers, and presentations

Naughton SX, Westfall S, Pasinetti GM “Immune Priming as a Driver of Gulf War Illness Pathology” Abstract/Poster No. VA-28, Gulf War Illness State of the Science, Virtual Conference August 18-19, 2020

d. Website(s) or other Internet site(s)

A recording for a virtual poster presentation based on this work can be found through the online conference proceedings available at : <https://www.cvent.com/d/37q773> .

e. Technologies or techniques

Nothing to report

f. Inventions, patent applications, and/or licenses

Nothing to report

g. Other Products

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

a. Individuals who have worked on the project

i. Dr. Sean X Naughton, PhD

Role: Post-Doctoral Fellow

Contribution: Responsible for overall design of the project and execution of experiments.

Funding Support: 10%

ii. Kyle Trageser, BS

Role: Research Assistant

Contribution: Assisting in the execution of experiments.

Funding Support: 5%

iii. Dr. Chad Smith, PhD

Role: Post-Doctoral Fellow

Contribution: Responsible for breeding and validating DREADD mice

Funding Support: 5%

iv. Dr. Giulio Pasinetti, MD PhD

Role: Principle Investigator

Contribution: Overall Experimental Design.

Funding Support: 15

b. Changes in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period

Nothing to report

c. Other Organizations involved as partners

Nothing to Report

8. Special Reporting Requirements

Nothing to Report

9. Appendices

Nothing to Report